Fecal calprotectin, a heterodimeric complex of the S100A8 and S100A9 proteins, has been approved by the FDA as an intestinal inflammation biomarker for diagnosing and predicting disease activity in patients with IBD [35,36]. This evidence concerns the gene S100A9 and inflammatory bowel disease.